MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-08-2023
Horizon Therapeutics Public Limited Company Operating Income 2011-2025 | HZNP
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Horizon Therapeutics Public Limited Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 617 M | 543 M | 490 M | 127 M | 37.9 M | -339 M | -146 M | 55.4 M | -8.49 M | -42.9 M | -78.9 M | -121 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 617 M | -339 M | 94.5 M |
Quarterly Operating Income Horizon Therapeutics Public Limited Company
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 143 M | 36 M | - | 161 M | 88.6 M | 194 M | - | 332 M | 139 M | -160 M | 240 M | 229 M | 37.9 M | -16.5 M | 54.7 M | 48.6 M | 25.1 M | -1.8 M | 82.5 M | 62.2 M | 10.6 M | -117 M | -67.3 M | -25.5 M | -185 M | -105 M | -130 M | -21.3 M | 31.5 M | -27.2 M | 38 M | 45.7 M | -33.2 M | 4.76 M | 8.98 M | -12 M | -7.1 M | 1.59 M | -5.76 M | -2.74 M | -15.8 M | -18.5 M | -22 M | -18.7 M | -18.3 M | -19.8 M | -89.2 M | -15.7 M | -8.75 M | -6.99 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 332 M | -185 M | 17.9 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-78.1 M | $ 4.77 | -0.42 % | $ 792 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-142 M | $ 3.03 | -0.33 % | $ 234 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 208.91 | -1.83 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
-24.6 M | $ 0.58 | -37.75 % | $ 160 K | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
-18.1 M | $ 1.24 | -2.36 % | $ 1.83 M | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 0.22 | 26.23 % | $ 479 M |  Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 94.4 | -0.67 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 26.93 | 0.45 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 9.56 | 0.8 % | $ 140 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 585.17 | -1.01 % | $ 44.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.46 | -2.72 % | $ 15.4 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 92.63 | 0.19 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 12.41 | 0.32 % | $ 817 M | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Celldex Therapeutics
CLDX
|
-195 M | $ 26.37 | -1.73 % | $ 1.7 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.05 | 0.56 % | $ 1.48 B | Britain |
 |
Cellectar Biosciences
CLRB
|
-39 M | $ 2.53 | -8.33 % | $ 30.9 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 10.85 | 0.37 % | $ 702 M | USA |
 |
Biogen
BIIB
|
7.04 B | $ 176.17 | -0.09 % | $ 25.7 B | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-447 M | - | - | $ 7.29 B | USA |